rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
26
|
pubmed:dateCreated |
1997-1-24
|
pubmed:abstractText |
As reported in our previous paper, a series of indole-3-acetamides which possessed potency and selectivity as inhibitors of human nonpancreatic secretory phospholipase A2(hnps-PLA2) was developed. The design of these compounds was based on information derived from x-ray crystal structures determined for complexes between the enzyme and its inhibitors. We describe here the further implementation of this structure-based design strategy and continued SAR development to produce indole-3-acetamides with additional functionalities which provide increased interaction with important residues within the enzyme active site. These efforts led to inhibitors with substantially enhanced potency and selectivity.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-2623
|
pubmed:author |
pubmed-author:AsayJ LJL,
pubmed-author:CENEKRR,
pubmed-author:CarlsonD GDG,
pubmed-author:ChirgadzeN YNY,
pubmed-author:ClawsonD KDK,
pubmed-author:DillardR DRD,
pubmed-author:DraheimS ESE,
pubmed-author:HartleyL WLW,
pubmed-author:JohnsonL MLM,
pubmed-author:JonesN DND,
pubmed-author:McKinneyE RER,
pubmed-author:MihelichE DED,
pubmed-author:OlkowskiJ LJL,
pubmed-author:SchevitzR WRW,
pubmed-author:SmithA CAC,
pubmed-author:SnyderD WDW,
pubmed-author:SommersC DCD,
pubmed-author:WeryJ PJP
|
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5137-58
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
|
pubmed:year |
1996
|
pubmed:articleTitle |
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.
|
pubmed:affiliation |
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
|
pubmed:publicationType |
Journal Article
|